RU2006119447A - Иммортализованные линии клеток птиц для получения вирусов - Google Patents
Иммортализованные линии клеток птиц для получения вирусов Download PDFInfo
- Publication number
- RU2006119447A RU2006119447A RU2006119447/13A RU2006119447A RU2006119447A RU 2006119447 A RU2006119447 A RU 2006119447A RU 2006119447/13 A RU2006119447/13 A RU 2006119447/13A RU 2006119447 A RU2006119447 A RU 2006119447A RU 2006119447 A RU2006119447 A RU 2006119447A
- Authority
- RU
- Russia
- Prior art keywords
- gene
- cell line
- protein
- line according
- viruses
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract 29
- 108050002653 Retinoblastoma protein Proteins 0.000 claims abstract 5
- 238000004519 manufacturing process Methods 0.000 claims abstract 5
- 230000003612 virological effect Effects 0.000 claims abstract 5
- 241000271566 Aves Species 0.000 claims abstract 2
- 230000001413 cellular effect Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 26
- 241000272525 Anas platyrhynchos Species 0.000 claims 7
- 230000006907 apoptotic process Effects 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 5
- 238000001890 transfection Methods 0.000 claims 5
- 230000009036 growth inhibition Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 102000001388 E2F Transcription Factors Human genes 0.000 claims 3
- 108010093502 E2F Transcription Factors Proteins 0.000 claims 3
- 241000701806 Human papillomavirus Species 0.000 claims 3
- 241000701244 Mastadenovirus Species 0.000 claims 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 241000701796 Fowl aviadenovirus 1 Species 0.000 claims 2
- 241000287828 Gallus gallus Species 0.000 claims 2
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 2
- 241001631646 Papillomaviridae Species 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims 2
- 210000001525 retina Anatomy 0.000 claims 2
- 210000002023 somite Anatomy 0.000 claims 2
- 229940123373 Adenovirus E1A gene Drugs 0.000 claims 1
- 241000272522 Anas Species 0.000 claims 1
- 241000272814 Anser sp. Species 0.000 claims 1
- 241001443586 Atadenovirus Species 0.000 claims 1
- 102000016736 Cyclin Human genes 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 1
- 101150013359 E7 gene Proteins 0.000 claims 1
- 101150059079 EBNA1 gene Proteins 0.000 claims 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 claims 1
- 241001135569 Human adenovirus 5 Species 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 229930193140 Neomycin Natural products 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000286209 Phasianidae Species 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 108700005077 Viral Genes Proteins 0.000 claims 1
- 108700019031 adenovirus E1B55K Proteins 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 210000002257 embryonic structure Anatomy 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 210000002219 extraembryonic membrane Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 101150024228 mdm2 gene Proteins 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 229960004927 neomycin Drugs 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 101150040063 orf gene Proteins 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000004853 protein function Effects 0.000 claims 1
- 229950010131 puromycin Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 229960000074 biopharmaceutical Drugs 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10251—Methods of production or purification of viral material
- C12N2710/10252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Manufacturing & Machinery (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (13)
1. Линия клеток птиц, иммортализованная с помощью невирусной трансфекции сочетанием вирусных и/или клеточных генов (гена (генов)), по меньшей мере, одного первого гена, воздействующего на функцию белка ретинобластомы, посредством разрушения комплексов между белками ретинобластомы и факторами транскрипции E2F, и, по меньшей мере, одного второго гена, воздействующего на белок p53 или представителя данного семейства, где второй ген представляет собой вирусный ген, кодирующий белок, предотвращающий индукцию торможения роста и апоптоза посредством p53, или клеточный ген, предотвращающий торможение роста и апоптоз посредством p53.
2. Линия клеток птиц по п.1, где первый ген подавляет контролирование контрольного пункта G1, и второй ген подавляет апоптоз, индуцированный первым геном.
3. Линия клеток по п.1, где
(i) линия клеток получена из эмбриона или вылупившейся курицы, утки, гуся, перепела и т. п., предпочтительно из курицы или утки; и/или
(ii) клетки, подвергаемые иммортализации, представляют собой первичные клетки, включающие фибробласты, клетки из выделенных сегментов тела (сомитов), или выделенные одиночные органы, включая ткани нейронов, мозга, сетчатки, почек, печени, сердца, мышц и экстраэмбриональные ткани и мембраны, предохраняющие эмбрион; и/или
(iii) иммортализация путем невирусной трансфекции включет, без ограничений, трансфекцию, опосредованную липосомами, дендримерами, и электропорацию; и/или
(iv) первый ген представляет собой ген вируса, обеспечивающий разрушение комплексов между белками ретинобластомы и факторами транскрипции E2F, такой как ген E1A аденовируса из мастаденовирусов, предпочтительно из мастаденовирусов группы С, ген E7 папилломавирусов, предпочтительно из вируса папилломы человека низкого риска (HPV) (такого как HPV1, HPV6 и HPV11, но не HPV16, HPV18), ген orf 22 аденовирусов птиц, открытые рамки считывания E43 из атаденовируса овцы и т.д.; или представляет собой ген клетки, обеспечивающий разрушение комплексов между белками ретинобластомы и факторами транскрипции E2F, такой как циклины D1, D2 или D3, мутированный CDK4, не восприимчивый к инактивации, посредством p16INK4a и т.д.; и/или
(v) второй ген представляет собой ген вируса, кодирующий белок, предотвращающий индукцию торможения роста и апоптоз, посредством p53, такой как белок E1B55K аденовируса всех групп, GAM-1 из CELO, белок E6 папилломавирусов, предпочтительно из HPV низкого риска (таких как HPV1, HPV6 и HPV11, но не HPV16, HPV18), или клеточный белок, предотвращающий торможение роста и апоптоз, посредством p53, такой как mdm2 и т.д.; и/или
(vi) первый ген и второй ген пространственно разделены гетерогенными последовательностями, или расположены на различных сегментах нуклеиновой кислоты или плазмидах.
4. Линия клеток по п.3, иммортализованная с помощью
(i) областей E1A (первый ген) и E1B (второй ген) аденовируса рода Mastadenovirus, предпочтительно указанные области E1A и E1B получены из аденовируса 5, более предпочтительно указанные области E1A содержат последовательность из п.о. 1193-2309 из SEQ ID NO:7 или последовательность, комплементарную п.о. 4230-3113 из SEQ ID NO:9, и указанные области E1B содержат последовательность из п.о. 1145-3007 из SEQ ID NO:8 или последовательность, комплементарную п.о. 2345-550, из SEQ ID NO:9; и/или
(ii) гены orf22 (первый ген) и GAM 1 (второй ген) из аденовируса, предпочтительно рода aviadenovirus CELO, которые, предпочтительно содержат последовательность представленную последовательностью, комплементарной 1252-635 п.о. из SEQ ID NO:10, и последовательность, комплементарную 3138-2290 п.о. из SEQ ID NO:10, соответственно; и/или
(iii) сочетания нуклеиновых кислот, кодирующих E1A и/или E1B с GAM-1 и/или Orf22, как определено выше в (i) и (ii).
5. Линия клеток по любому из пп.1-4, которая
(i) дополнительно несет неприродные функциональные последовательности, включая, без ограничений, трансгены, такие как гены, комплементарные дефицитным вирусам (например, EBNA1 и т.д.), промоторы (например, PGK-, EF1.alpha-, CMV-промотор, tk-промотор и т.д.), энхансеры (например, RSV-LTR), селективные маркеры, такие как резистентности к неомицину, резистентности к пуромицину и т.д.; и/или
(ii) подходит для получения биологических препаратов или вирусов, включая вакцинные штаммы и рекомбинантные вирусные векторы.
6. Линия клеток по любому из пп.1-4, которая
(i) не обладает активностью обратной транскриптазы; и/или
(ii) получена в результате иммортализации первичной клетки, происходящей из эмбрионов уток или вылупившихся уток; и/или
(iii) получена из экстраэмбриональной оболочки; и/или
(iv) культивирована в среде определенного химического состава, которая предпочтительно не содержит сыворотку животного.
7. Линия клеток по любому из пп.1-4, которая представляет собой линию клеток 12A07-A10 птицы (DSM ACC2695).
8. Способ получения линии клеток по любому из пп.1-7, который содержит трансформирование/трансфицирование исходной клетки первым и вторым геном.
9. Способ по п.8, который содержит невирусную трансфекцию исходной клетки.
10. Применение линии клеток по любому из пп.1-7 для получения биологических препаратов или вирусов.
11. Способ получения вирусов, который включает
(i) контактирование указанных вирусов с линией клеток по любому из пп.1-7 и/или
(ii) культивирование указанных вирусов в указанной линии клеток.
12. Способ по п.11 для получения вируса оспы, предпочтительно штамма MVA, в линии клеток утки, предпочтительно в линии клеток, происходящей из сомитов утки или нейронной ткани утки, еще более предпочтительно - из сетчатки утки.
13. Способ получения рекомбинантных белков, который включает
(i) введение гена, кодирующего рекомбинантный белок, функционально связанного с промотором, в линию клеток по любому из пп.1-7,
(ii) культивирование указанной модифицированной линии клеток и
(iii) сбор рекомбинантного белка.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03025158A EP1528101A1 (en) | 2003-11-03 | 2003-11-03 | Immortalized avian cell lines for virus production |
EP03025158.1 | 2003-11-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006119447A true RU2006119447A (ru) | 2007-12-20 |
RU2359999C2 RU2359999C2 (ru) | 2009-06-27 |
Family
ID=34400514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006119447/13A RU2359999C2 (ru) | 2003-11-03 | 2004-11-03 | Иммортализованные линии клеток птиц для получения вирусов |
Country Status (18)
Country | Link |
---|---|
US (2) | US8940534B2 (ru) |
EP (4) | EP1528101A1 (ru) |
JP (1) | JP4658953B2 (ru) |
KR (1) | KR101027755B1 (ru) |
CN (1) | CN1934243B (ru) |
AT (2) | ATE460473T1 (ru) |
AU (1) | AU2004285089B2 (ru) |
BR (1) | BRPI0415622B8 (ru) |
CA (1) | CA2544462C (ru) |
CY (1) | CY1110272T1 (ru) |
DE (2) | DE602004025996D1 (ru) |
DK (2) | DK1939281T4 (ru) |
ES (1) | ES2309578T3 (ru) |
PL (1) | PL1685243T3 (ru) |
PT (1) | PT1685243E (ru) |
RU (1) | RU2359999C2 (ru) |
SI (1) | SI1685243T1 (ru) |
WO (1) | WO2005042728A2 (ru) |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2531565C (en) * | 2003-07-22 | 2014-02-11 | Vivalis | Production of poxviruses with adherent or non adherent avian cell lines |
DE602005024827D1 (de) | 2004-09-09 | 2010-12-30 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
CN101365480B (zh) | 2005-11-01 | 2014-11-05 | 诺华疫苗和诊断有限两合公司 | 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗 |
CN102727885A (zh) | 2005-11-04 | 2012-10-17 | 诺华疫苗和诊断有限公司 | 包含颗粒佐剂和免疫增强剂组合的流感疫苗 |
CA2628152C (en) | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
US20110180430A1 (en) | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
JP2009514844A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション |
WO2007052155A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
EP1783210A1 (en) * | 2005-11-08 | 2007-05-09 | ProBioGen AG | Productivity augmenting protein factors, novel cell lines and uses thereof |
KR20110110853A (ko) | 2006-01-27 | 2011-10-07 | 노파르티스 파르마 아게 | 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신 |
CA2646349A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
EP3456348A1 (en) | 2006-09-11 | 2019-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
CA2671629C (en) | 2006-12-06 | 2017-08-15 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
EP1985305A1 (en) * | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
CA2692200A1 (en) | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
KR101528379B1 (ko) * | 2007-07-03 | 2015-06-16 | 트랜스진 에스.에이. | 불멸화된 조류 세포주들 |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
WO2009081172A1 (en) | 2007-12-24 | 2009-07-02 | Novartis Ag | Assays for adsorbed influenza vaccines |
EP2257622B1 (en) * | 2008-02-25 | 2017-03-22 | Nanotherapeutics, Inc. | Method for producing continuous cell lines |
US8679839B2 (en) * | 2008-03-04 | 2014-03-25 | Probiogen Ag | Cell line from rousettus as host cell for pathogen amplification |
EP2098590A1 (en) | 2008-03-04 | 2009-09-09 | ProBioGen AG | Cell line from Rousettus as host cell for pathogen amplification |
AU2009227674C1 (en) | 2008-03-18 | 2015-01-29 | Seqirus UK Limited | Improvements in preparation of influenza virus vaccine antigens |
EP2310494A1 (en) * | 2008-06-25 | 2011-04-20 | ProBioGen AG | Cell line for propagation of highly attenuated alphaviruses |
EP2199385A1 (en) | 2008-12-16 | 2010-06-23 | ProBioGen AG | Specific and persistent activation of heat shock response in cell lines using a viral factor |
WO2010079081A1 (en) | 2009-01-07 | 2010-07-15 | Glaxosmithkline Biologicals S.A. | Methods for recovering a virus or a viral antigen produced by cell culture |
CA2750055A1 (en) | 2009-02-06 | 2010-08-12 | Glaxosmithkline Biologicals S.A. | Method for purifying viruses using a density gradient |
CA2752039A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
CA2752041A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
PL2396032T3 (pl) | 2009-02-10 | 2017-05-31 | Seqirus UK Limited | Szczepionki przeciw grypie o obniżonych zawartościach skwalenu |
BE1019643A3 (fr) | 2009-04-27 | 2012-09-04 | Novartis Ag | Vaccins de protection contre la grippe. |
HUE058971T2 (hu) | 2009-07-15 | 2022-09-28 | Glaxosmithkline Biologicals Sa | RSV F fehérjekészítmények és eljárások azok elõállítására |
EP2475385A1 (en) | 2009-09-10 | 2012-07-18 | Novartis AG | Combination vaccines against respiratory tract diseases |
WO2011040527A1 (ja) * | 2009-09-30 | 2011-04-07 | 国立大学法人帯広畜産大学 | α-ガラクトースエピトープを発現するトランスジェニック鳥類、ウイルス及びワクチン |
WO2011095596A1 (en) | 2010-02-04 | 2011-08-11 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
CN102791860A (zh) | 2010-03-08 | 2012-11-21 | 诺华有限公司 | 检测胞内病原体的方法 |
WO2011127316A1 (en) | 2010-04-07 | 2011-10-13 | Novartis Ag | Method for generating a parvovirus b19 virus-like particle |
EP2563909A1 (en) | 2010-04-26 | 2013-03-06 | Novartis AG | Improved production of virus replicon particles in packaging cells |
CA2797059A1 (en) | 2010-05-03 | 2011-11-10 | Glaxosmithkline Biologicals S.A. | Novel method |
US9426989B2 (en) | 2010-05-06 | 2016-08-30 | Novartis Ag | Organic peroxide compounds for microorganism inactivation |
WO2011145081A1 (en) | 2010-05-21 | 2011-11-24 | Novartis Ag | Influenza virus reassortment method |
PL2575873T3 (pl) | 2010-06-01 | 2016-06-30 | Novartis Ag | Zatężanie i liofilizacja antygenów szczepionkowych grypy |
PL2575872T3 (pl) | 2010-06-01 | 2021-02-22 | Seqirus UK Limited | Zatężanie antygenów szczepionkowych grypy bez liofilizacji |
WO2012006293A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
EP2605792B1 (en) | 2010-08-20 | 2014-12-10 | Novartis AG | Soluble needle arrays for delivery of influenza vaccines |
JP2013544504A (ja) | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
EP3257943B1 (en) * | 2010-11-02 | 2019-09-11 | Helmholtz-Zentrum für Infektionsforschung GmbH | Methods and vectors for cell immortalisation |
WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
PL2667892T3 (pl) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | Schemat szczepień przeciwko rsv |
ES2651143T3 (es) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
US20140287402A1 (en) | 2011-06-27 | 2014-09-25 | Valneva | Method for screening cells |
CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
MX2014004214A (es) | 2011-10-11 | 2014-05-07 | Novartis Ag | Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes. |
WO2013054199A2 (en) | 2011-10-12 | 2013-04-18 | Novartis Ag | Cmv antigens and uses thereof |
GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
WO2013057715A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
EP2660316A1 (en) | 2012-05-02 | 2013-11-06 | Helmholtz-Zentrum für Infektionsforschung GmbH | Avian cell line and its use in production of protein |
JP2015522580A (ja) | 2012-07-06 | 2015-08-06 | ノバルティス アーゲー | 免疫学的組成物およびその使用 |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
MX2015006377A (es) | 2012-11-20 | 2015-07-21 | Glaxosmithkline Biolog Sa | Trimeros prefusion de f de vsr. |
CN103060376A (zh) * | 2012-12-11 | 2013-04-24 | 上海实验动物研究中心 | 一种禽腺病毒转移载体及其制备方法 |
CA2897752A1 (en) | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
US20140255447A1 (en) * | 2013-03-05 | 2014-09-11 | Biomune Company | Production of avian embryo cells |
EP3039127B1 (en) | 2013-08-30 | 2020-01-01 | GlaxoSmithKline Biologicals S.A. | Large scale production of viruses in cell culture |
CN104726409B (zh) * | 2013-12-19 | 2017-12-29 | 普莱柯生物工程股份有限公司 | 一种永生化的鸭胚肝细胞系的制备方法和应用 |
US20150282503A1 (en) * | 2014-04-02 | 2015-10-08 | Synageva Biopharma Corp. | Producing Therapeutic Proteins |
EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
EP3169341B1 (en) | 2014-07-16 | 2019-06-05 | Transgene SA | Oncolytic virus for expression of immune checkpoint modulators |
RU2694318C2 (ru) * | 2014-12-04 | 2019-07-11 | Интервет Интернэшнл Б.В. | Иммортализованные фибробласты эмбриона цыпленка |
EP3031822A1 (en) | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
JP6719468B2 (ja) | 2014-12-16 | 2020-07-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 大規模なウイルス精製方法 |
PL3233130T3 (pl) | 2014-12-17 | 2021-11-22 | Fundacion Para La Investigacion Medica Aplicada | Konstrukty kwasów nukleinowych i wektory do terapii genowej do zastosowania w leczeniu choroby wilsona |
ES2784264T3 (es) | 2014-12-17 | 2020-09-23 | Fundacion Para La Investig Medica Aplicada | Construcciones de ácido nucleico y vectores de terapia génica para su uso en el tratamiento de la enfermedad de Wilson y otras afecciones |
EP3047856A1 (en) | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
US11013795B2 (en) | 2015-06-26 | 2021-05-25 | Seqirus UK Limited | Antigenically matched influenza vaccines |
JP6830070B2 (ja) | 2015-07-07 | 2021-02-17 | セキラス ユーケー リミテッドSeqirus UK Limited | インフルエンザ効力アッセイ |
CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
CN107012122A (zh) * | 2016-12-12 | 2017-08-04 | 江苏省农业科学院 | 一种永生化鸡胚胎肝细胞系及其制备方法和用途 |
ES2905478T3 (es) | 2016-12-28 | 2022-04-08 | Transgene Sa | Virus oncolíticos y moléculas terapéuticas |
WO2018176103A1 (en) | 2017-03-30 | 2018-10-04 | The University Of Queensland | "chimeric molecules and uses thereof" |
KR20240113607A (ko) | 2017-06-21 | 2024-07-22 | 트랜스진 | 개인 맞춤형 백신 |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
EP4400174A2 (en) | 2017-09-01 | 2024-07-17 | The Francis Crick Institute Limited | Immunoregulatory molecules and uses therefor |
EP3973973A1 (en) | 2017-10-31 | 2022-03-30 | KaliVir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
WO2019092002A1 (en) | 2017-11-07 | 2019-05-16 | Valneva Se | Pharmaceutical compositions for treatment or prevention of viral infections |
WO2019109051A1 (en) | 2017-12-01 | 2019-06-06 | Encoded Therapeutics, Inc. | Engineered dna binding proteins |
EP3794127A1 (en) | 2018-05-14 | 2021-03-24 | Vivet Therapeutics | Gene therapy vectors comprising s/mar sequences |
WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
WO2020012037A1 (en) | 2018-07-13 | 2020-01-16 | Valneva Se | Method for rescuing and producing a virus in avian cells |
EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
CN110396496B (zh) * | 2018-09-30 | 2023-06-20 | 湖北省农业科学院畜牧兽医研究所 | 一种鸭小肠上皮细胞的培养方法及应用 |
WO2020074690A1 (en) | 2018-10-12 | 2020-04-16 | Vivet Therapeutics | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) |
BR112021008434A2 (pt) | 2018-11-07 | 2021-09-28 | Vivet Therapeutics | Transgene abcb11 otimizado por códon para o tratamento de colestase intra-hepática familiar progressiva tipo 2 (pfic2) |
CN109321516A (zh) * | 2018-11-07 | 2019-02-12 | 贵州大学 | 一种鸭原代肝细胞分离及培养方法 |
WO2020102723A1 (en) | 2018-11-16 | 2020-05-22 | Encoded Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
SG11202104869SA (en) | 2018-11-23 | 2021-06-29 | Valneva Se | Food products comprising avian stem cells |
SG11202106898VA (en) | 2018-12-28 | 2021-07-29 | Transgene Sa | M2-defective poxvirus |
EP3686276A1 (en) * | 2019-01-28 | 2020-07-29 | Freie Universität Berlin | Production of viruses in continuously growing epithelial cell lines derived from chicken gut |
AU2020299718A1 (en) | 2019-07-02 | 2022-02-24 | Fundacion Para La Investigacion Medica Aplicada | cPLA2e inducing agents and uses thereof |
CA3146900A1 (en) | 2019-07-21 | 2021-01-28 | Glaxosmithkline Biologicals Sa | Therapeutic viral vaccine |
US20230201334A1 (en) | 2019-07-24 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
JP2023502650A (ja) | 2019-11-18 | 2023-01-25 | セキラス ピーティーワイ リミテッド | 遺伝子再集合インフルエンザウイルスを産生するための方法 |
WO2021209897A1 (en) | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
CA3189238A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
MX2023000968A (es) | 2020-08-06 | 2023-03-01 | Fundacion Para La Investig Medica Aplicada | Particulas virales para usarse en el tratamiento contra tauopatias tales como enfermedad de alzheimer mediante terapia genica. |
US20230265456A1 (en) | 2020-08-10 | 2023-08-24 | Fundacion Para La Investigacion Medica Aplicada | Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis |
JP2023544264A (ja) | 2020-10-09 | 2023-10-23 | ユーシービー バイオファルマ エスアールエル | 核酸構築物、ウイルスベクター及びウイルス粒子 |
EP4267197A1 (en) | 2020-12-23 | 2023-11-01 | Vivet Therapeutics | Minimal bile acid inducible promoters for gene therapy |
WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
WO2022149142A2 (en) | 2021-01-10 | 2022-07-14 | Supermeat The Essence Of Meat Ltd. | Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry |
EP4032547A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
BR112023022681A2 (pt) | 2021-04-30 | 2024-01-23 | Kalivir Immunotherapeutics Inc | Vírus oncolíticos para expressão modificada de mhc |
WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
TW202321458A (zh) | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
WO2023067595A1 (en) | 2021-10-18 | 2023-04-27 | Supermeat The Essence Of Meat Ltd. | Methods for preparing a food ingredient and compositions produced thereby |
CA3234666A1 (en) | 2021-10-28 | 2023-05-04 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
CN114350601B (zh) * | 2021-12-21 | 2022-12-27 | 广东省华晟生物技术有限公司 | 樱桃谷鸭成纤维细胞系及其构建方法与应用 |
WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
CN114908053A (zh) * | 2022-04-24 | 2022-08-16 | 上海交通大学 | 孔雀成纤维永生化细胞系的制备方法及其在病毒扩增中的应用 |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
CN116496992B (zh) * | 2023-04-24 | 2023-12-01 | 江苏省家禽科学研究所 | 一种鸡胚成肌永生化细胞及其构建方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL122614A0 (en) * | 1995-06-15 | 1998-08-16 | Introgene Bv | Packaging systems for human recombinant adenovirus to be used in gene therapy |
KR970010968A (ko) | 1995-08-24 | 1997-03-27 | 윤원영 | 오리 배 세포를 이용한 에리스로포이틴의 발현 시스템 |
US5989805A (en) | 1995-10-27 | 1999-11-23 | Board Of Trustees Operating Michigan State University | Immortal avian cell line to grow avian and animal viruses to produce vaccines |
FR2749022B1 (fr) | 1996-05-23 | 2001-06-01 | Rhone Merieux | Cellules aviaires immortelles |
US5830723A (en) | 1996-08-13 | 1998-11-03 | Regents Of The University Of Minnesota | Method for immortalizing chicken cells |
US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
FR2767335B1 (fr) | 1997-08-14 | 2001-09-28 | Ct Nat D Etudes Veterinaires E | Adenovirus aviaire celo recombinant comme vecteur vaccinant |
DE19955558C2 (de) * | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
CN1139655C (zh) * | 2001-08-23 | 2004-02-25 | 北京大学人民医院 | 一种人卵巢癌永生化细胞株及其建立方法 |
DE60336653D1 (de) | 2002-08-07 | 2011-05-19 | Bavarian Nordic As | Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren |
NZ538575A (en) | 2002-09-05 | 2007-03-30 | Bavarian Nordic As | Method for the amplification of a virus wherein primary avian cells are cultivated in a serum-free medium comprising growth factors and attachment factors |
CA2531565C (en) | 2003-07-22 | 2014-02-11 | Vivalis | Production of poxviruses with adherent or non adherent avian cell lines |
-
2003
- 2003-11-03 EP EP03025158A patent/EP1528101A1/en not_active Withdrawn
-
2004
- 2004-11-03 DK DK08101999.4T patent/DK1939281T4/da active
- 2004-11-03 EP EP04798154A patent/EP1685243B1/en active Active
- 2004-11-03 CA CA2544462A patent/CA2544462C/en active Active
- 2004-11-03 JP JP2006537316A patent/JP4658953B2/ja active Active
- 2004-11-03 AT AT08101999T patent/ATE460473T1/de active
- 2004-11-03 EP EP10002423A patent/EP2192173A1/en not_active Withdrawn
- 2004-11-03 PL PL04798154T patent/PL1685243T3/pl unknown
- 2004-11-03 KR KR1020067010635A patent/KR101027755B1/ko active IP Right Grant
- 2004-11-03 AT AT04798154T patent/ATE398672T1/de active
- 2004-11-03 PT PT04798154T patent/PT1685243E/pt unknown
- 2004-11-03 SI SI200430843T patent/SI1685243T1/sl unknown
- 2004-11-03 DK DK04798154T patent/DK1685243T3/da active
- 2004-11-03 DE DE602004025996T patent/DE602004025996D1/de active Active
- 2004-11-03 CN CN2004800397218A patent/CN1934243B/zh active Active
- 2004-11-03 AU AU2004285089A patent/AU2004285089B2/en active Active
- 2004-11-03 US US10/578,043 patent/US8940534B2/en active Active
- 2004-11-03 DE DE602004014526T patent/DE602004014526D1/de active Active
- 2004-11-03 ES ES04798154T patent/ES2309578T3/es active Active
- 2004-11-03 RU RU2006119447/13A patent/RU2359999C2/ru active
- 2004-11-03 EP EP08101999.4A patent/EP1939281B2/en active Active
- 2004-11-03 BR BRPI0415622A patent/BRPI0415622B8/pt active IP Right Grant
- 2004-11-03 WO PCT/EP2004/052789 patent/WO2005042728A2/en active IP Right Grant
-
2008
- 2008-09-18 CY CY20081101019T patent/CY1110272T1/el unknown
-
2012
- 2012-07-26 US US13/558,567 patent/US20120288916A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006119447A (ru) | Иммортализованные линии клеток птиц для получения вирусов | |
JP2007510409A5 (ru) | ||
CN1942583B (zh) | Hpv58l1在酵母中的最优化表达 | |
Bubb et al. | DNA sequence of the HPV-16 E5 ORF and the structural conservation of its encoded protein | |
CN109810953A (zh) | 去除tk基因的重组天坛株溶瘤痘苗病毒及其制备和应用 | |
Hoppe-Seyler et al. | Activation of human papillomavirus type 18 E6–E7 oncogene expression by transcription factor Sp1 | |
ES2215805T3 (es) | Composicion farmaceutica para el tratamiento de los tumores e infecciones por papilomavirus. | |
Tan et al. | The Mastomys natalensis papillomavirus: nucleotide sequence, genome organization, and phylogenetic relationship of a rodent papillomavirus involved in tumorigenesis of cutaneous epithelia | |
Fang et al. | The human papillomavirus type 11 E1^ E4 protein is not essential for viral genome amplification | |
Ilves | Virus-cell interactions in the replication cycle of bovine papillomavirus type 1 | |
Fang et al. | Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures | |
Phelps et al. | Functional and sequence similarities between HPV16 E7 and adenovirus E1A | |
Yutsudo et al. | Human papillomavirus type 17 transcripts expressed in skin carcinoma tissue of a patient with epidermodysplasia verruciformis | |
Cerni et al. | Successive steps in the process of immortalization identified by transfer of separate bovine papillomavirus genes into rat fibroblasts. | |
Nalcacioglu et al. | Amsacta moorei entomopoxvirus encodes a functional DNA photolyase (AMV025) | |
CN100402655C (zh) | 人神经营养素-3受体基因重组腺病毒构建方法 | |
CN110205304A (zh) | 一种重组天坛株溶瘤痘苗病毒及制备方法和应用 | |
JP2009514544A5 (ru) | ||
RU2008122920A (ru) | Усиливающий продуктивность белковый фактор, новые клеточные линии и их применение | |
Brazeau et al. | Simian varicella virus open reading frame 63/70 expression is required for efficient virus replication in culture | |
Potenza et al. | A recombinant vaccinia virus infects Xenopus melanophores | |
CN110205307A (zh) | 去除vgf基因的重组天坛株溶瘤痘苗病毒及制备和应用 | |
CN118360416B (zh) | Ledgf基因在抗禽白血病性状选育中的应用 | |
AU2021100454A4 (en) | Expression Vector of Goat Poxvirus Vaccine Strain | |
Smith et al. | Control of papovaviral DNA replication |